Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0090 | Nevirapine

Molecular Formula C15H14N4O
Molecular Weight 266.3
Structure
State solid
Volume of distribution * 1.21 ± 0.09 L/kg [apparent volume of distribution, healthy adults, IV] Nevirapine is capable of crossing the placenta and is found in breast milk.
Route of elimination Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Protein binding 60% bound to plasma protein.
Half life 45 hours
Absorption Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state.

J

J05AR07 Stavudine, lamivudine and nevirapine


[J05AR] Antivirals for treatment of HIV infections, combinations


[J05A] DIRECT ACTING ANTIVIRALS


[J05] ANTIVIRALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

J05AR05 Zidovudine, lamivudine and nevirapine


[J05AR] Antivirals for treatment of HIV infections, combinations


[J05A] DIRECT ACTING ANTIVIRALS


[J05] ANTIVIRALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

J05AG01 Nevirapine


[J05AG] Non-nucleoside reverse transcriptase inhibitors


[J05A] DIRECT ACTING ANTIVIRALS


[J05] ANTIVIRALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 23 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (17.39%): Harmful if swallowed [Warning Acute toxicity, oral]


H412 (95.65%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P273, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LDLo oral 400mg/kg (400mg/kg) Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 2209, 1999.
dog LD oral > 3200mg/kg (3200mg/kg) Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 2209, 1999.

  • Acquired immunodeficiency syndrome

  • Autoimmune disorder

  • Dermatitis

  • Hepatotoxicity

  • Infection

  • Rash

  • Arthralgia (0.02)

  • Stevens-Johnson syndrome (0.003)

  • Abdominal pain

  • Agranulocytosis

  • Anaemia

  • Asthenia

  • Body temperature increased

  • Dermatitis

  • Diarrhoea

  • Fatigue

  • Gastrointestinal pain

  • Headache

  • Hepatitis

  • Hepatotoxicity

  • Liver function test abnormal

  • Musculoskeletal discomfort

  • Myalgia

  • Nausea

  • Neutropenia

  • Rash

    • 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
    11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody) 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
    11-Cyclopropyl-4-methyl-5H-dipyrido[3,2-b 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one
    11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one
    11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one 129618-40-2
    1vrt 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0(3),]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
    2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one 2hny 5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-
    618N402 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
    99DK7FVK1H AB0013383 AB00393001-13
    AB00393001-15 AB00393001_16 AB00393001_17
    AB07544 AB2000266 AC-643
    AK143126 AKOS005504351 ALBB-027264
    BBL010768 BCP05587 BDBM1434
    BI-RG 587 BI-RG 587;NSC 641530;NVP BI-RG-587
    BI-RG-587 BI-RG-587 & CD4-IgG BIDD:GT0326
    BIRG 0587 BIRG 0587 BIRG 587
    BIRG-0587 BIRG-587 BIRG587
    BIRG587 C07263 C15H14N4O
    CAS-129618-40-2 CCG-100939 CHEBI:63613
    CHEMBL57 CPD000048458 CS-2252
    CTK8E7455 Certified Reference Material D00435
    DB-041930 DB00238 DSSTox_CID_10787
    DSSTox_GSID_31797 DSSTox_RID_78889 DTXSID7031797
    F2173-0607 FT-0607215 H954
    HMS2051J09 HMS2231O23 HMS3264D21
    HMS3371E03 HMS3393J09 HMS3655I08
    HMS3715B10 HSDB 7164 HSDB 7164
    HY-10570 KS-00000KZF KS-5019
    LS-2289 MCULE-8608154492 MFCD00866928
    MFCD00866928 (98%) MLS000084585 MLS000759409
    MLS001055309 MLS001201730 MLS001424058
    MLS006011423 N0922 N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
    NC00189 NCGC00065890-02 NCGC00065890-03
    NCGC00065890-04 NCGC00065890-05 NCGC00065890-07
    NCGC00258324-01 NEV NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
    NQDJXKOVJZTUJA-UHFFFAOYSA-N NSC 641530 NSC 641530
    NSC-641530 NSC-759902 NSC641530
    NSC759902 NVP NVP
    Nevirapine & CD4-IgG Nevirapine & PRO 140 Nevirapine (JAN/USP/INN)
    Nevirapine (Viramune) Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard Nevirapine [USAN:INN]
    Nevirapine [USAN:USP:INN:BAN] Nevirapine anhydrous Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard
    Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard Nevirapine solution, 1.0 mg/mL in methanol, certified reference material Nevirapine, 98%
    Nevirapine, Pharmaceutical Secondary Standard Nevirapine,(S) Opera_ID_934
    Pharmakon1600-01503842 Q263713 R3924
    RT-014690 S1742 SAM001246551
    SC-17266 SCHEMBL3318 SMR000048458
    ST24038235 STK580320 SW197569-2
    SY009679 Tox21 110982 Tox21_110982
    Tox21_110982_1 Tox21_200770 UNII-99DK7FVK1H
    Viramune Viramune (TN) Viramune IR
    Viramune XR Viramune(TM) Viramune;BI-RG 587
    Z1695906730 ZINC4778 nevirapine

    DrugBank Name Nevirapine
    DrugBank DB00238
    CAS Number 129618-40-2
    PubChem Compound 4463
    KEGG Compound ID C07263
    KEGG Drug D00435
    PubChem.Substance 46506789
    ChEBI 63613
    PharmGKB PA450616
    ChemSpider 4308
    BindingDB 1434.0
    TTD DAP000184
    Wikipedia Nevirapine
    HET NVP
    DPD 11796

    1. Dykens et al. (2007)